Positive results for bamlanivimab (LY-CoV555) for preventing COVID-19 at nursing homes in the BLAZE-2 trial

In this study (n=965) of bamlanivimab, a monoclonal antibody against the surface spike protein of SARS-CoV-2 reduced the frequency of symptomatic COVID-19 vs placebo (OR 0.43, p=0.00021). Serious adverse events were reported at a similar frequency in both arms

Source:

Biospace Inc.